ORGANIZATIONAL ASPECTS OF SUBLINGUAL ALLERGEN-SPECIFIC IMMUNOTHERAPY

Abstract

Aim. The aim of the study was to analyze the organizational aspects of allergen-specific immunotherapy (ASIT) including peculiarities of choosing patients for treatment, choice of drug and method of allergen introduction, time of onset and duration of therapy. Materials and methods. Patients, who in 2015 addressed to one of commercial allergic centers of Perm on account of respiratory allergic disease, were under observation. The condition for patients to be chosen for ASIT was availability of clinically significant allergic rhinitis and rhinoconjunctivivtis, elevated IgE level. Results. One hundred thirty seven patients received ASIT (102 children and 35 adults; age - from 3 to 57 years) with allergic rhinoconjunctivivtis and mild bronchial asthma. In etiological structure, there predominated pollinoses - 90,5 %, including 72,5 % - early spring trees, 9,4 % - house allergy. Duration of treatment was 88,6 ± 3,89 days. Conclusions. When choosing ASIT method, in particular, therapy with commercial allergens, the most popular method among patients is sublingual. The time to start therapy for the early spring pollinosis is not later than the beginning of February, for cereals and meadow plants - the beginning of March, for weed - the beginning of April - depending on regional peculiarities of pollination. Sublingual ASIT is characterized by good tolerance; local temporary allergic reactions are observed at the stage of choosing the dose in 11 % of patients, who do not keep to hypoallergenic diet.

Keywords

Allergen-specific immunotherapy / sublingual ASIT / pollinosis / house sensibility

References

[1] Аллергология. Фармакотерапия без ошибок: руководство для врачей / под ред. Р.М. Хаитова. М.: Е-ното 2013; 496.

[2] Аллергология. Федеральные клинические рекомендации / под ред. Р.М. Хаитова, Н.И. Ильиной. М.: Фармарус Принт Медиа 2014; 126.

[3] Астафьева Н.Г., Гамова И.В., Удовиченко Е.Н,. Перфилова И.А,. Кобзев Д.Ю,. Вачугова Л.К. Место аллергенспецифической иммунотерапии в лечении атопии. Эффективная фармакология 2012; 1: 6-18.

[4] Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М.: Фармарус Принт Медиа 2010; 228.

[5] Курбачева О.М., Муажон Ф., Павлова К.С., Храбина М. Феномен перекрестной реактивности аллергенов и аллергенспецифической иммунотерапии. Российский аллергологический журнал 2010; 1: 32-39.

[6] Минаева Н.В., Малыгина К.В., Корюкина И.П. Специфическая иммунотерапия (СИТ) в лечении поллинозов у детей. Аллергология и иммунология в педиатрии 2009; 3 (18): 43.

[7] Calderon M., Cardona V., Demoly P One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswering questions. Allergy 2012; 67 (4): 462-467.

[8] Petersen B.N., Janniche H., Munch E.P., Wihl J.A., Bowadt H., Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. I. Clinical results from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43 (5): 353-362.

[9] Valenta R., Vrtala S., Focke-Tejkl M., Tvardosz A. Swoboda I., Budajska-Schretter A., Spitzauer S., Kraft D. Synthetic and genetically engineered allergen derivates for specific immunotherapy of type 1 allergy. Clin. Allergy. Immunol. 2002; 16: 495-517.

[10] Wihl J.A., Ipsen H., Petersen B.N., Munch E.P., Janniche H., Lowenstein H. Immunotherapy with partially purified and standardized tree pollen extracts. II. Results of skin prick tests and nasal provocation tests from a three-year double-blind study of patients treated with pollen extracts either of birch or combinations of alder, birch and hazel. Allergy 1988; 43 (5): 363-369.

RIGHTS & PERMISSIONS

Plakhina K.V., Minaeva N.V.